25575-88-6

Basic information

• Product Name: methyl N-(5-oxo-L-prolyl)-L-histidinate
• Synonyms: methyl N-(5-oxo-L-prolyl)-L-histidinate;5-Oxo-L-Pro-L-His-OMe
• CAS NO: 25575-88-6
• Molecular Formula: C₁₂H₁₆N₄O₄
• Molecular Weight: 280.27984
• EINECS: 247-113-3
• Mol File: 25575-88-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 711.1°Cat760mmHg
• Flash Point: 383.9°C
• Appearance: /
• Density: 1.354g/cm³
• Vapor Pressure: 4.54E-20mmHg at 25°C
• Refractive Index: 1.564
• CAS DataBase Reference: methyl N-(5-oxo-L-prolyl)-L-histidinate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl N-(5-oxo-L-prolyl)-L-histidinate(25575-88-6)
• EPA Substance Registry System: methyl N-(5-oxo-L-prolyl)-L-histidinate(25575-88-6)

Safety Data

• Hazardous Substances Data: 25575-88-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H16N4O4/c1-20-12(19)9(4-7-5-13-6-14-7)16-11(18)8-2-3-10(17)15-8/h5-6,8-9H,2-4H2,1H3,(H,13,14)(H,15,17)(H,16,18)/t8-,9-/m0/s1

Upstream product

• 98-79-3 L-Pyroglutamic acid 
• 1499-46-3 L-Histidine methyl ester 
• 59850-85-0 N-hydroxysuccinimide ester of pyroglutamic acid 
• 7389-87-9 L-histidine methyl ester dihydrochloride 
• 5910-47-4 L-pyroglutamic acid 2,4,5-trichlorophenyl ester 

Downstream Products

• 57818-00-5 <*>Glu-His-Pip-OMe 
• 52434-75-0 pGlu-His-Trp-Ser-Tyr 
• 142822-22-8 L-pyroglutamyl-L-histidyl-L-trypthophyl-L-seryl-L-tyrosine tert-butyl ester 
• 51871-39-7 L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosine methyl ester 
• 51952-40-0 L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-glycyl-L-leucyl-L-arginyl-L-prolyl-glycine amide hydrochloride 
• 25575-89-7 L-Pyroglutamyl-L-histidine Hydrazide 

Relevant articles and documents

AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES

The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treatment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirovirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.

Synthesis of Gonadoliberin, a Gonadotropin Releasing Hormone

A simple laboratory synthesis of gonadoliberin was elaborated basing on classical solution methods and using minimal protection of the side-chain functions.In the final step a hexapeptide segment was condensed with the corresponding tetrapeptide and the obtained product was purified by a single step silica gel chromatography.The total efficiency of the whole synthesis was 15percent.

Synthesis of the thyrotropin-releasing hormone.

-